Compare IPAR & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPAR | IRON |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 1995 | 2020 |
| Metric | IPAR | IRON |
|---|---|---|
| Price | $95.96 | $69.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $116.60 | $103.18 |
| AVG Volume (30 Days) | 206.1K | ★ 407.4K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ 2.34 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $1,317,700,000.00 | N/A |
| Revenue This Year | $3.86 | N/A |
| Revenue Next Year | $7.89 | $283.52 |
| P/E Ratio | $71.58 | ★ N/A |
| Revenue Growth | ★ 21.26 | N/A |
| 52 Week Low | $77.21 | $40.00 |
| 52 Week High | $142.50 | $99.50 |
| Indicator | IPAR | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 60.08 | 55.45 |
| Support Level | $92.30 | $64.39 |
| Resistance Level | $98.64 | $71.53 |
| Average True Range (ATR) | 2.97 | 3.18 |
| MACD | 0.87 | 0.23 |
| Stochastic Oscillator | 89.54 | 64.38 |
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.